Alt tag

Audio Library

Vascular Adviser News

Keith Fox About The Updated CCS ESC Guidelines 2019

© Bayer AG 2021 

 

Despite current optimised medical treatment, patients with CAD or PAD remain at high risk of cardiovascular events. With the European approval of rivaroxaban vascular dose, 2.5 mg twice daily, plus aspirin, and new European guidelines’ recommendations on vascular protection, we are in exciting times. Join James Rudd in this episode of the Thrombosis Adviser Podcast series discussing together with Keith Fox - Professor of Cardiology at the University of Edinburgh - how to interpret the ESC 2019 Guidelines on Chronic Coronary Syndrome.

 

PP-XAR-ALL-1571-1

Dr. Alexander Cohen highlighting the updated ESC recommendations

© Bayer AG 2021 

 

Recent real-world evidence, as well as results from Phase 3 trials, have shed light on the efficacy and safety of NOACs for the treatment of VTE in different patient populations. My name is James Rudd and in this episode of the Thrombosis Adviser podcast series I am delighted to welcome Ander Cohen – Vascular Physician and Epidemiologist at Guy’s and St Thomas’ NHS Foundation Trust in London – to discuss practical considerations for the use of NOACs in the treatment of patients with VTE.

 

PP-XAR-ALL-1570-1